시장보고서

상품코드

1877439

세계의 항감염제 시장 : 약제 클래스별, 적응증별, 투여 경로별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 점유율 및 예측(2025-2032년)

Anti-Infective Drugs Market, By Drug Class, By Indication, By Route of Administration, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 378 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항감염제 시장 규모는 2024년 1,342억 6,721만 달러로 평가되었고, 2025-2032년 3.1%의 성장률을 보일 것으로 예측됩니다.

항감염제 시장은 박테리아, 바이러스, 곰팡이, 기생충에 의한 감염증의 예방 및 치료에 사용되는 의약품의 개발 및 유통에 초점을 맞추었습니다. 병원 내 감염 발생률 증가와 항생제 내성 증가로 화이자와 글락소 스미스클라인 등 제약사들은 신규 항균제 연구개발 파이프라인의 확대를 추진하고 있습니다. 예를 들어, 세계보건기구(WHO)의 보고에 따르면 2023년까지 495만 명 이상이 약제 내성 세균 감염으로 사망할 것으로 예상되어 첨단 치료법에 대한 긴급한 수요가 발생하고 있습니다. 생명공학 기업과 학계와의 협력은 차세대 항생제 및 항바이러스제 개발을 뒷받침하고 있습니다. 그러나 높은 개발 비용과 항생제의 수익성 저하로 인해 중소기업 시장 진입을 가로막고 있습니다. 신흥국에서의 치료 접근성 확대와 병용요법에 대한 관심이 높아짐에 따라 기업들이 제품 포트폴리오를 다양화하고 환자 치료 결과를 개선할 수 있는 기회를 제공합니다.

항감염제 시장 역학

증가하는 감염 부담과 항균제 내성으로 인해 항감염제 혁신이 가속화되고 있습니다.

감염률 상승과 항균제 내성 확대는 세계보건기구(WHO)와 제약회사에 항감염제 분야의 혁신 가속화를 촉구하고 있습니다. WHO에 따르면, 항균제 내성으로 인해 연간 127만 명이 사망하고, 약제 내성 감염과 관련된 사망자는 368만 명에 달하는 것으로 보고되고 있습니다. 이에 따라 미국 질병통제예방센터(CDC) 등의 기관은 신속 진단 도구와 새로운 항생제 개발을 위한 노력에 자금을 지원하고 있습니다. 정부도 항생제 파이프라인 감소에 대응하기 위해 AMR 액션펀드 등 민관협력을 지원하고 있습니다. 이러한 노력은 새로운 유형의 항균제, 표적 항바이러스제 및 병용요법 개발을 촉진하여 내성 병원균에 보다 효과적으로 대응할 수 있도록 돕고 있습니다.

항감염제 시장 : 세분화 분석

세계 항감염제 시장은 약물 유형, 적응증, 투여 경로, 최종 사용자, 지역에 따라 분류됩니다.

약효군별 시장은 항균제, 항진균제, 항기생충제, 항바이러스제, 항진균제, 항진균제 등 4개 카테고리로 나뉩니다. 항균제는 세균성 감염 치료의 보급으로 가장 큰 점유율을 차지하고 있으며, 바이러스 감염 증가를 배경으로 항바이러스제가 그 뒤를 잇고 있습니다. 침습성 진균 감염증 증가에 따라 항진균제가 그 뒤를 잇고 있으며, 항기생충제는 규모는 작지만 전 세계적으로 중요한 틈새 시장을 형성하고 있습니다.

폐렴, 패혈증, 결핵, 결핵, 피부사상균증, 칸디다증, 간염 바이러스 감염, HIV 감염, 코로나19 바이러스, 메티실린 내성 황색포도상구균(MRSA) 등 9가지 적응증에 따라 시장을 세분화했습니다. 폐렴은 전 세계 질병부담이 높은 질환으로 1위를 차지하고 있으며, 집중치료 수요 증가에 따라 패혈증이 그 뒤를 잇고 있습니다. HIV 및 간염 감염은 지속적인 치료 프로그램으로 높은 점유율을 유지하고 있으며, 결핵과 MRSA는 항생제 개발을 주도하고 있습니다. 칸디다증, 피부사상균증, 코로나19는 표적 치료 부문을 구성합니다.

항감염제 시장 - 지역별 분석

북미는 탄탄한 의료 인프라와 화이자와 머크 등 기업들의 지속적인 연구개발 투자로 항감염제 시장을 선도하고 있습니다. 2018년 화이자는 바이오엔텍과 제휴하여 mRNA 기반 항감염제 응용을 코로나19 외의 다른 분야로 확대하며 지역 내 입지를 강화했습니다. 유럽은 EU 자금의 항균제 내성(AMR) 대책 프로그램, GSK와 BARDA의 신규 항생제 공동 개발 등의 협력으로 북미에 이어 두 번째로 큰 규모를 유지하고 있습니다. 아시아태평양은 감염률 증가와 치료 접근성 향상을 위한 정부의 이니셔티브(예: 인도의 AMR 대책 국가행동계획에 따른 항균제 적정 사용 촉진 및 국내 생산 지원 등)을 배경으로 주요 성장 거점으로 부상하고 있습니다. 라틴아메리카와 중동 및 아프리카에서는 백신 도입과 공중보건 캠페인이 확대되고 있습니다.

항감염제 시장 - 국가별 분석

북미 항감염제 시장에서는 미국이 선진화된 의료 시스템과 풍부한 임상시험 파이프라인을 바탕으로 선도적인 위치를 차지하고 있습니다. 2024년, 머크는 프로메테우스 바이오사이언스를 인수하여 면역학 및 감염질환 분야의 제품 포트폴리오를 강화하고 연구 역량을 강화했습니다. 미국 정부 산하 생물의학첨단연구개발국(BARDA)은 항생제 개발을 가속화하기 위해 GSK, 베네톡스 파마슈티컬스(Benetox Pharmaceuticals)와 같은 기업과의 공동연구에 지속적으로 자금을 지원하고 있습니다. CDC가 보고한 다제내성 감염 사례 증가에 따라 병원에서는 새로운 치료법과 진단 도구의 도입이 진행되고 있습니다. FDA의 강력한 규제 프레임워크와 GAIN 법과 같은 인센티브는 새로운 항감염 약물의 혁신과 상용화를 더욱 촉진하고 있습니다.

항감염제 시장 : 경쟁 구도

항감염제 시장 경쟁 구도는 화이자, 머크, GSK, 존슨앤드존슨, 로슈 등 주요 기업들이 연구개발 및 전략적 제휴를 통해 제품 포트폴리오를 확대하면서 형성되고 있습니다. 2020년 화이자는 길리어드 사이언스와 제휴하여 내성 감염을 대상으로 하는 새로운 항바이러스제 조합을 공동 개발했습니다. GSK는 BARDA와의 협업을 통해 차세대 항생제 개발을 지원하고, 존슨앤드존슨은 슈퍼박테리아 대응을 위한 박테리오파지 연구에 투자하고 있습니다. 베네톡스 파마슈티컬스, 이테람 테라퓨틱스 등 중소 바이오텍 기업들은 제조 및 유통 규모 확대를 위해 대형 제약사와의 제휴를 추진하고 있습니다. 이러한 제휴, 인수, 정부 지원 프로그램의 조합은 경쟁을 심화시키고 의약품 혁신을 가속화하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : 항감염제업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- AbbVie
- AstraZeneca
- Bayer
- Cipla
- Dr. Reddy's Laboratories
- Gilead Sciences
- GlaxoSmithKline(GSK)
- Glenmark Pharmaceuticals
- Johnson &Johnson
- Lupin
- Merck &Co.
- Novartis
- Pfizer
- Roche
- Sandoz(Novartis)
- Sanofi
- Sun Pharmaceutical Industries
- Teva Pharmaceutical Industries
- Viatris
- ViiV Healthcare
- Others

제13장 AnalystView의 전방위적 분석

LSH 25.12.22

The Anti-Infective Drugs Market size was valued at US$ 134,267.21 Million in 2024, expanding at a CAGR of 3.1% from 2025 to 2032.

The anti-infective drugs market focuses on the development and distribution of medications used to prevent and treat infections caused by bacteria, viruses, fungi, and parasites. The rising incidence of hospital-acquired infections and increasing antibiotic resistance have pushed pharmaceutical companies like Pfizer and GlaxoSmithKline to expand their R&D pipelines for novel antimicrobials. For example, the WHO reported that over 4.95 million deaths in 2023 were linked to drug-resistant bacterial infections, creating urgent demand for advanced therapies. Partnerships between biotech firms and academia are supporting the development of next-generation antibiotics and antivirals. However, high development costs and declining profitability of antibiotics discourage smaller players from entering the market. Expanding access to treatments in emerging economies and the rising focus on combination therapies present opportunities for companies to diversify product portfolios and improve patient outcomes.

Anti-Infective Drugs Market- Market Dynamics

Rising Infection Burden and Antimicrobial Resistance Fuel Innovation in Anti-Infective Drugs

Rising infection rates and growing antimicrobial resistance are pushing global health agencies and pharmaceutical companies to accelerate innovation in anti-infective drugs. According to the WHO, antimicrobial resistance was responsible for 1.27 million direct deaths a year, with an additional 3.68 million deaths associated with drug-resistant infections. This has led organizations like the U.S. Centers for Disease Control and Prevention (CDC) to fund initiatives for rapid diagnostic tools and novel antibiotics. Governments are also supporting public-private partnerships, such as the AMR Action Fund, to address the dwindling antibiotic pipeline. These efforts are encouraging the development of new classes of antimicrobials, targeted antivirals, and combination therapies to combat resistant pathogens more effectively.

Anti-Infective Drugs Market- Segmentation Analysis:

The Global Anti-Infective Drugs Market is segmented on the basis of Drug Class, Indication, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: Antibacterial, Antifungals, Antiparasitic, and Antivirals. Antibacterials hold the highest share due to widespread bacterial infection treatments, followed by antivirals driven by rising viral outbreaks. Antifungals rank next with the growing incidence of invasive fungal infections, while antiparasitics represent a smaller but crucial niche segment globally.

The market is divided into nine categories based on Indication: Pneumonia, Sepsis, Tuberculosis, Dermatophytosis, Candidiasis, Hepatitis virus infection, HIV infection, Covid-19 Virus, and Methicillin-resistant Staphylococcus Aureus. Pneumonia leads due to its high global burden, followed by sepsis, as critical care demand rises. HIV and hepatitis infections hold strong shares with ongoing treatment programs, while tuberculosis and MRSA drive antibiotic development. Candidiasis, dermatophytosis, and COVID-19 represent targeted therapeutic segments.

Anti-Infective Drugs Market- Geographical Insights

North America leads the anti-infective drugs market due to strong healthcare infrastructure and continuous R&D investments by players like Pfizer and Merck. In 2018, Pfizer collaborated with BioNTech to expand mRNA-based anti-infective applications beyond COVID-19, strengthening its regional presence. Europe follows closely, supported by EU-funded antimicrobial resistance (AMR) programs and partnerships like GSK's collaboration with BARDA to develop new antibiotics. Asia-Pacific is emerging as a key growth hub, driven by rising infection rates and government efforts to improve access to treatments; for instance, India's National Action Plan on AMR promotes antibiotic stewardship and local production. Latin America and MEA witness growing vaccine adoption and public health campaigns.

Anti-Infective Drugs Market- Country Insights

The United States dominates the North American anti-infective drugs market, supported by advanced healthcare systems and a robust pipeline of clinical trials. In 2024, Merck acquired Prometheus Biosciences to strengthen its immunology and infectious disease portfolio, enhancing its research capabilities. The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) continues funding collaborations with companies like GSK and Venatorx Pharmaceuticals to accelerate antibiotic development. Rising cases of multidrug-resistant infections reported by the CDC are prompting hospitals to adopt newer therapies and diagnostic tools. Strong regulatory frameworks from the FDA and incentives like the GAIN Act further encourage innovation and commercialization of novel anti-infectives.

Anti-Infective Drugs Market- Competitive Landscape:

The competitive landscape of the anti-infective drugs market is shaped by leading players such as Pfizer, Merck, GSK, Johnson & Johnson, and Roche, who are expanding portfolios through R&D and strategic deals. In 2020, Pfizer partnered with Gilead Sciences to co-develop new antiviral combinations targeting resistant infections. GSK's collaboration with BARDA supports the development of next-generation antibiotics, while Johnson & Johnson invests in bacteriophage research to combat superbugs. Smaller biotech firms like Venatorx Pharmaceuticals and Iterum Therapeutics are entering collaborations with big pharma to scale manufacturing and distribution. This mix of partnerships, acquisitions, and government-backed programs is intensifying competition and accelerating drug innovation.

Recent Developments:

In February 2025, the Merieux Foundation, SPIM, and WHO launched a new Guide to Prescribing Anti-infective Drugs in Madagascar, updating antibiotic chapters, diagnostics, and integrating WHO's 2023 AWaRe classification to support standardized prescribing and strengthen national AMR action plans.

In February 2025, the U.S. FDA approved EMBLAVEO(TM) (aztreonam + avibactam) for adult patients with complicated intra-abdominal infections when few or no treatment options exist, including infections by E. coli and Klebsiella.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTI-INFECTIVE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie
AstraZeneca
Bayer
Cipla
Dr. Reddy's Laboratories
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Johnson & Johnson
Lupin
Merck & Co.
Novartis
Pfizer
Roche
Sandoz (Novartis)
Sanofi
Sun Pharmaceutical Industries
Teva Pharmaceutical Industries
Viatris
ViiV Healthcare
Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Antibacterial
B-Lactams
Quinolones
Macrolides
Tetracycline
Aminoglycoside
Others
Antifungals
Azoles
Echinocandins
Polyenes
Antiparasitics
Antivirals

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Pneumonia
Sepsis
Tuberculosis
Dermatophytosis
Candidiasis
Hepatitis virus infection
HIV infection
Covid-19 Virus
Methicillin-resistant Staphylococcus Aureus
Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Topical
Inhalation

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Clinics
Retail Pharmacies
Institutional Buyers

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Anti-Infective Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Anti-Infective Drugs Market Snippet by Drug Class
- 2.1.2. Anti-Infective Drugs Market Snippet by Indication
- 2.1.3. Anti-Infective Drugs Market Snippet by Route of Administration
- 2.1.4. Anti-Infective Drugs Market Snippet by End-User
- 2.1.5. Anti-Infective Drugs Market Snippet by Country
- 2.1.6. Anti-Infective Drugs Market Snippet by Region
2.2. Competitive Insights

3. Anti-Infective Drugs Key Market Trends

3.1. Anti-Infective Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Anti-Infective Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Anti-Infective Drugs Market Opportunities
3.4. Anti-Infective Drugs Market Future Trends

4. Anti-Infective Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Anti-Infective Drugs Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Anti-Infective Drugs Market Landscape

6.1. Anti-Infective Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Anti-Infective Drugs Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 7.1.2. Antibacterial
  - 7.1.2.1. B-Lactams
  - 7.1.2.2. Quinolones
  - 7.1.2.3. Macrolides
  - 7.1.2.4. Tetracycline
  - 7.1.2.5. Aminoglycoside
  - 7.1.2.6. Others
- 7.1.3. Antifungals
  - 7.1.3.1. Azoles
  - 7.1.3.2. Echinocandins
  - 7.1.3.3. Polyenes
- 7.1.4. Antiparasitics
- 7.1.5. Antivirals

8. Anti-Infective Drugs Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Pneumonia
- 8.1.3. Sepsis
- 8.1.4. Tuberculosis
- 8.1.5. Dermatophytosis
- 8.1.6. Candidiasis
- 8.1.7. Hepatitis virus infection
- 8.1.8. HIV infection
- 8.1.9. Covid-19 Virus
- 8.1.10. Methicilin-resistant Staphylococcus Aureus
- 8.1.11. Others

9. Anti-Infective Drugs Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Injectable
- 9.1.4. Topical
- 9.1.5. Inhalation

10. Anti-Infective Drugs Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Clinics
- 10.1.4. Retail Pharmacies
- 10.1.5. Institutional Buyers

11. Anti-Infective Drugs Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Anti-Infective Drugs Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Anti-Infective Drugs Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Anti-Infective Drugs Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Anti-Infective Drugs Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Anti-Infective Drugs Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Anti-Infective Drugs Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AbbVie
- 12.2.2. AstraZeneca
- 12.2.3. Bayer
- 12.2.4. Cipla
- 12.2.5. Dr. Reddy's Laboratories
- 12.2.6. Gilead Sciences
- 12.2.7. GlaxoSmithKline (GSK)
- 12.2.8. Glenmark Pharmaceuticals
- 12.2.9. Johnson & Johnson
- 12.2.10. Lupin
- 12.2.11. Merck & Co.
- 12.2.12. Novartis
- 12.2.13. Pfizer
- 12.2.14. Roche
- 12.2.15. Sandoz (Novartis)
- 12.2.16. Sanofi
- 12.2.17. Sun Pharmaceutical Industries
- 12.2.18. Teva Pharmaceutical Industries
- 12.2.19. Viatris
- 12.2.20. ViiV Healthcare
- 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us